Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

Eton advances ET-900 for epileptic spasms, but human data and revenue are years away.

What the company is saying

Eton Pharmaceuticals is announcing the launch of ET-900, a clinical development program targeting infantile and epileptic spasms using mecasermin, a recombinant IGF-1 already marketed as INCRELEX in the United States. The company highlights a newly signed license agreement with Baylor College of Medicine for patent rights covering IGF-1 use in spasms, emphasizing the scientific rationale from Baylor-led research. CEO Sean Brynjelsen frames the program as addressing a critical unmet need, citing high resistance rates to current therapies and the potential for mecasermin to fill this gap. The announcement leans heavily on preclinical animal data, stating a 50% reduction in daily spasm counts and complete elimination in 20% of treated animals, while acknowledging the lack of FDA approval for this indication. Eton stresses the urgency and severity of refractory epileptic spasms, referencing prevalence figures and the limitations of existing treatments. The tone is optimistic and forward-looking, but the company is clear that efficacy and safety in humans remain unproven and that a Phase 2 trial is only now moving forward.

What the data suggests

The disclosed numbers show that approximately 2,500 children are diagnosed with infantile spasms in the United States each year, establishing a defined but rare target population. Preclinical animal studies cited by Eton show a 50% reduction in daily spasm counts and complete elimination of spasms in 20% of treated animals with recombinant IGF-1, supporting the scientific rationale but not guaranteeing human efficacy. A peer-reviewed study indicates that about 50% of children with infantile spasms do not respond to initial treatments, underscoring the high unmet need. The Phase 2 trial will enroll up to 20 children aged 2–18 years across three sites, with dosing planned for Q1 2027, and will assess both efficacy and safety endpoints. The announcement provides no financial data, revenue projections, or cost disclosures for the program. All current evidence is preclinical, with no human efficacy or safety data yet available for mecasermin in this indication. The only realised milestones are the IND submission and the Baylor license agreement.

Analysis

The announcement is upbeat and emphasizes the urgent need for new therapies, but the actual measurable progress is limited to preclinical animal data and the submission of a research IND for a Phase 2 trial. No human efficacy or safety data are available, and initial patient enrollment is not expected until Q1 2027, making any clinical or commercial benefit long-term. The language highlights unmet need and potential impact, but the only realised milestones are the licensing agreement and IND submission. There is no disclosure of financial terms, capital outlay, or profitability metrics, and no immediate earnings impact is implied. The narrative is somewhat inflated by projecting hope and clinical promise based on animal data, but the company is transparent about the unproven status of mecasermin for this indication.

Risk flags

• ●The program is at an early stage, with all efficacy data limited to animal models; there is no guarantee that the 50% reduction in spasm counts or the 20% elimination rate will translate to human patients, making clinical risk high.
• ●Enrollment for the Phase 2 trial is not expected to begin until Q1 2027, introducing a long execution timeline and potential for delays in recruitment, data collection, and regulatory review.
• ●Mecasermin is not FDA-approved for infantile or epileptic spasms, and its safety and efficacy for these uses are unestablished, so regulatory risk remains substantial and the pathway to approval is uncertain.
• ●The announcement does not disclose any financial terms, costs, or projected revenues associated with ET-900, leaving investors unable to assess the program's capital requirements or potential return on investment.

Bottom line

Eton Pharmaceuticals has initiated a new clinical program, ET-900, for refractory infantile and epileptic spasms, leveraging preclinical animal data showing a 50% reduction in spasm frequency and a 20% complete response rate. The company has secured a license from Baylor College of Medicine and submitted an IND for a Phase 2 trial, but enrollment is not expected until early 2027, and all efficacy evidence is preclinical. The target patient population is small, with about 2,500 new diagnoses annually in the United States and high rates of treatment resistance, highlighting the unmet need but also the limited commercial scale. No financial data or cost projections are provided, and the program's success depends entirely on future human trial results. Investors should recognize that this is a long-term, high-risk development effort with no near-term revenue or clinical readouts. The most important takeaway is that Eton is positioning itself in a high-need niche, but tangible value creation will require positive human data and regulatory progress, both of which are several years away.

Announcement summary

(NASDAQ:ETON) Eton Pharmaceuticals, Inc. announced the launch of ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Mecasermin is a recombinant form of IGF-1 and is the active ingredient in INCRELEX, which Eton markets in the United States. Eton has entered into a license agreement with Baylor College of Medicine covering patent rights related to the use of IGF-1 for the treatment of spasms. Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals, stated that there is a significant and urgent need for new therapeutic approaches due to high rates of resistance to current therapies. Research led by Dr. John W. Swann, Ph.D., Distinguished Emeritus Professor of Pediatrics and Neuroscience at Baylor College of Medicine and funded by CURE Epilepsy, identified impaired IGF-1 signaling as a potential contributor to epileptic spasms. In an animal model, treatment with recombinant human IGF-1 reduced daily spasm counts by approximately 50% and eliminated spasms in 20% of treated animals. A research IND has been submitted for an investigator-sponsored Phase 2 trial to evaluate mecasermin for efficacy, safety, and tolerability in children with refractory epileptic spasms. The study will be sponsored by the University of Chicago and is expected to enroll up to 20 patients ages 2–18 years across three sites: University of Chicago, Baylor College of Medicine, and UCLA. Patients eligible for the study are those whose spasms have not responded to, or who have been unable to tolerate, hormonal therapy and vigabatrin. The treatment protocol involves twice-daily subcutaneous injections during an initial three- to five-week period, with an additional treatment course available based on clinical response. The study will assess spasm resolution, changes in daily spasm frequency, and resolution or improvement of associated EEG abnormalities, as well as safety, tolerability, and adaptive functioning. Mecasermin is not FDA-approved for the treatment of infantile or epileptic spasms, and its safety and efficacy for these uses have not been established. Initial enrollment and dosing are targeted for the first quarter of 2027. According to the American Academy of Pediatrics, approximately 2,500 children are diagnosed with infantile spasms in the United States each year. A peer-reviewed study published in Epilepsy & Behavior reports that seizures in approximately 50% of children with infantile spasms fail to improve with initial treatment attempts. Eton Pharmaceuticals currently has twelve rare disease products and six additional product candidates in late-stage development, including ET-900.

Disagree with this article?